Status | Study |
NOT_YET_RECRUITING |
Study Name: A Study of Omaveloxolone in Children With Friedreich's Ataxia Condition: Friedreich Ataxia Date: 2023-09-13 Interventions: One dose of omaveloxolone will be taken orally.Dosage to be determined based on age and PK data from prior Parts. |
RECRUITING |
Study Name: Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study Condition: Friedreich Ataxia Date: 2023-08-18 |
Not yet recruiting |
Study Name: TCA Cycle in the Dentate in Friedreich's Ataxia Condition: Friedreich Ataxia Date: 2017-04-18 Interventions: Device: MR MR |
Recruiting |
Study Name: Rosuvastatin (Crestor) in Friedreich Ataxia Condition: Friedreich Ataxia Date: 2016-03-05 Interventions: Drug: Rosuvastatin Daily oral administration of Rosuvastatin (10 mg) for 3 months |
Recruiting |
Study Name: (+) Epicatechin to Treat Friedreich's Ataxia Condition: Friedreich's Ataxia Date: 2016-01-18 Interventions: Drug: (+)-Epicatechin 25mg (+)-Epicatechin capsules. Starting dose 75mg total daily dose (one 25mg cap t |
Recruiting |
Study Name: Methylprednisolone Treatment of Friedreich Ataxia Condition: Friedreich Ataxia Date: 2015-04-16 Interventions: Drug: Methylprednisolone Oral tablets of methylprednisolone 8 mg. Subjects will receive a monthly prescr |
Recruiting |
Study Name: Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA) Condition: Friedreich's Ataxia Date: 2014-11-12 Interventions: Procedure: Cardiac magnetic resonance imaging (CMR) |
Recruiting |
Study Name: RTA 408 Capsules in Patients With Friedreich's Ataxia - MOXIe Condition: Friedreich Ataxia Date: 2014-09-30 Interventions: Drug: Omaveloxolone Capsules, 2.5 mg |
Recruiting |
Study Name: Patient Registry of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) Condition: Friedreich's Ataxia Date: 2014-02-19 |
Completed |
Study Name: EPI-743 in Friedreich's Ataxia Point Mutations Condition: Friedreich's Ataxia Date: 2013-10-10 Interventions: Drug: EPI-743 EPI-743 (alpha-tocotrienol quinone) is a small molecule therapeutic that was rationally de |